m6A-centered Drug Response Information
General Information of the Drug (ID: M6ADRUG0063)
| Name |
Meclofenamate sodium
|
||||
|---|---|---|---|---|---|
| Status | Approved | [1] | |||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C14H10Cl2NNaO2
|
||||
| InChI |
InChI=1S/C14H11Cl2NO2.Na/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;/h2-7,17H,1H3,(H,18,19);/q;+1/p-1
|
||||
| InChIKey |
OGPIIGMUPMPMNT-UHFFFAOYSA-M
|
||||
| PubChem CID | |||||
| TTD Drug ID | |||||
| DrugBank ID | |||||
Full List of m6A Targets Related to This Drug
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)
| In total 2 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
| Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
| Target Regulation | Down regulation | |||
| Pathway Response | mTOR signaling pathway | hsa04150 | ||
| Cell Process | RNA decay | |||
| Cell growth and death | ||||
| Cell autophagy | ||||
| In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
| SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
| Experiment 2 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
| Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
| Pathway Response | mTOR signaling pathway | hsa04150 | ||
| Cell Process | RNA decay | |||
| Cell growth and death | ||||
| Cell autophagy | ||||
| In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
| SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Serine/threonine-protein kinase mTOR (MTOR)
| In total 2 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
| Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | mTOR signaling pathway | hsa04150 | ||
| Autophagy | hsa04140 | |||
| Cell Process | RNA decay | |||
| Cell growth and death | ||||
| Cell autophagy | ||||
| In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
| SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
| Experiment 2 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
| Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
| Pathway Response | mTOR signaling pathway | hsa04150 | ||
| Autophagy | hsa04140 | |||
| Cell Process | RNA decay | |||
| Cell growth and death | ||||
| Cell autophagy | ||||
| In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
| SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Drug
| In total 4 item(s) under this drug | ||
| Crosstalk ID: M6ACROT03337 | ||
| m6A Regulator | YTH domain-containing family protein 2 (YTHDF2) | |
| m6A Target | Cyclic AMP-dependent transcription factor ATF-4 (ATF4) | |
| Epigenetic Regulator | Histone acetyltransferase p300 (P300) | |
| Regulated Target | Histone H3 lysine 18 lactylation (H3K18la) | |
| Crosstalk relationship | Histone modification → m6A | |
| Disease | Colorectal cancer | |
| Crosstalk ID: M6ACROT03343 | ||
| m6A Regulator | YTH domain-containing family protein 2 (YTHDF2) | |
| m6A Target | Serine/threonine-protein kinase mTOR (MTOR) | |
| Epigenetic Regulator | Histone acetyltransferase p300 (P300) | |
| Regulated Target | Histone H3 lysine 18 lactylation (H3K18la) | |
| Crosstalk relationship | Histone modification → m6A | |
| Disease | Colorectal cancer | |
| Crosstalk ID: M6ACROT03435 | ||
| m6A Regulator | Fat mass and obesity-associated protein (FTO) | |
| m6A Target | Cyclic AMP-dependent transcription factor ATF-4 (ATF4) | |
| Epigenetic Regulator | Histone deacetylase 1 (HDAC1) | |
| Regulated Target | Histone H3 lysine 27 acetylation (H3K27ac) | |
| Crosstalk relationship | Histone modification → m6A | |
| Disease | Colorectal cancer | |
| Crosstalk ID: M6ACROT03441 | ||
| m6A Regulator | Fat mass and obesity-associated protein (FTO) | |
| m6A Target | Serine/threonine-protein kinase mTOR (MTOR) | |
| Epigenetic Regulator | Histone deacetylase 1 (HDAC1) | |
| Regulated Target | Histone H3 lysine 27 acetylation (H3K27ac) | |
| Crosstalk relationship | Histone modification → m6A | |
| Disease | Colorectal cancer | |